| ［1］ |
Zhang H，Zhou XD，Shapiro MD，et al.Global burden of metabolic diseases，1990-2021 ［J］.Metabolism，2024，160：155999.
|
| ［2］ |
Cui B，Wang G，Li P，et al.Disease-specific mortality and major adverse cardiovascular events after bariatric surgery：a meta-analysis of age，sex，and BMI-matched cohort studies ［J］.Int J Surg，2023，109（3）：389-400.
|
| ［3］ |
中国医师协会外科医师分会肥胖和糖尿病外科医师委员会.中国肥胖及2型糖尿病外科治疗指南（2019版） ［J］.中国实用外科杂志，2019，39（4）：301-306.
|
| ［4］ |
Muller TD，Clemmensen C，Finan B，et al.Anti-obesity therapy：from rainbow pills to polyagonists ［J］.Pharmacol Rev，2018，70（4）：712-746.
|
| ［5］ |
Wilding J，Batterham RL，Calanna S，et al.Once-weekly semaglutide in adults with overweight or obesity ［J］.N Engl J Med，2021，384（11）：989-1002.
|
| ［6］ |
Sjolund K，Sanden G，Hakanson R，et al.Endocrine cells in human intestine：an immunocytochemical study ［J］.Gastroenterology，1983，85（5）：1120-1130.
|
| ［7］ |
Larsen PJ，Tang-Christensen M，Holst JJ，et al.Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem ［J］.Neuroscience，1997，77（1）：257-270.
|
| ［8］ |
Campbell SA，Golec DP，Hubert M，et al.Human islets contain a subpopulation of glucagon-like peptide-1 secreting alpha cells that is increased in type 2 diabetes ［J］.Mol Metab，2020，39：101014.
|
| ［9］ |
Blundell J，Finlayson G，Axelsen M，et al.Effects of once-weekly semaglutide on appetite，energy intake，control of eating，food preference and body weight in subjects with obesity ［J］.Diabetes Obes Metab，2017，19（9）：1242-1251.
|
| ［10］ |
Gabery S，Salinas CG，Paulsen SJ，et al.Semaglutide lowers body weight in rodents via distributed neural pathways ［J］.JCI Insight，2020，5（6）：e133429.
|
| ［11］ |
O'neil PM，Birkenfeld AL，Mcgowan B，et al.Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity：a randomised，double-blind，placebo and active controlled，dose-ranging，phase 2 trial ［J］.Lancet，2018，392（10148）：637-649.
|
| ［12］ |
Pratley R，Amod A，Hoff ST，et al.Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes （PIONEER 4）：a randomised，double-blind，phase 3a trial ［J］.Lancet，2019，394（10192）：39-50.
|
| ［13］ |
Davies M，Faerch L，Jeppesen OK，et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity，and type 2 diabetes （STEP 2）：a randomised，double-blind，double-dummy，placebo-controlled，phase 3 trial ［J］.Lancet，2021，397（10278）：971-984.
|
| ［14］ |
Rubino D，Abrahamsson N，Davies M，et al.Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity：The STEP 4 Randomized Clinical Trial ［J］.JAMA，2021，325（14）：1414-1425.
|
| ［15］ |
Wilding J，Batterham R L，Davies M，et al.Weight regain and cardiometabolic effects after withdrawal of semaglutide：The STEP 1 trial extension ［J］.Diabetes Obes Metab，2022，24（8）：1553-1564.
|
| ［16］ |
Astrup A，Carraro R，Finer N，et al.Safety，tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog，liraglutide ［J］.Int J Obes （Lond），2012，36（6）：843-854.
|
| ［17］ |
Mroz PA，Finan B，Gelfanov V，et al.Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism［J］.Mol Metab，2019，20：51-62.
|
| ［18］ |
Coskun T，Sloop KW，Loghin C，et al.LY3298176，a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus：From discovery to clinical proof of concept ［J］.Mol Metab，2018，18：3-14.
|
| ［19］ |
Gastaldelli A，Cusi K，Fernandez LL，et al.Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes （SURPASS-3 MRI）：a substudy of the randomised，open-label，parallel-group，phase 3 SURPASS-3 trial ［J］.Lancet Diabetes Endocrinol，2022，10（6）：393-406.
|
| ［20］ |
Finan B，Ma T，Ottaway N，et al.Unimolecular dual incretins maximize metabolic benefits in rodents，monkeys，and humans ［J］.Sci Transl Med，2013，5（209）：209ra151.
|
| ［21］ |
Samms RJ，Coghlan MP，Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1？ ［J］.Trends Endocrinol Metab，2020，31（6）：410-421.
|
| ［22］ |
Frias JP，Davies MJ，Rosenstock J，et al.Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes ［J］.N Engl J Med，2021，385（6）：503-515.
|
| ［23］ |
Jastreboff AM，Aronne LJ，Ahmad NN，et al.Tirzepatide once weekly for the treatment of obesity ［J］.N Engl J Med，2022，387（3）：205-216.
|
| ［24］ |
Wadden TA，Chao AM，Machineni S，et al.Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity：the SURMOUNT-3 phase 3 trial ［J］.Nat Med，2023，29（11）：2909-2918.
|
| ［25］ |
Aronne LJ，Sattar N，Horn DB，et al.Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity：the SURMOUNT-4 randomized clinical trial ［J］.JAMA，2024，331（1）：38-48.
|
| ［26］ |
Rosenstock J，Wysham C，Frias JP，et al.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes （SURPASS-1）：a double-blind，randomised，phase 3 trial ［J］.Lancet，2021，398（10295）：143-155.
|
| ［27］ |
Kleinert M，Sachs S，Habegger KM，et al.Glucagon regulation of energy expenditure ［J］.Int J Mol Sci，2019，20（21）：5407.
|
| ［28］ |
Ambery P，Parker V E，Stumvoll M，et al.MEDI0382，a GLP-1 and glucagon receptor dual agonist，in obese or overweight patients with type 2 diabetes：a randomised，controlled，double-blind，ascending dose and phase 2a study ［J］.Lancet，2018，391（10140）：2607-2618.
|
| ［29］ |
Ali MM，Hafez A，Abdelgalil MS，et al.Impact of cotadutide drug on patients with type 2 diabetes mellitus：a systematic review and metaanalysis ［J］.BMC Endocr Disord，2022，22（1）：113.
|
| ［30］ |
Schiavon M，Visentin R，Gobel B，et al.Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide ［J］.Diabetes Obes Metab，2021，23（8）：1795-1805.
|
| ［31］ |
Nahra R，Wang T，Gadde KM，et al.Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes：a 54-week randomized phase 2b study ［J］.Diabetes Care，2021，44（6）：1433-1442.
|
| ［32］ |
Boyle CN，Lutz TA，Le Foll C.Amylin - its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity ［J］.Mol Metab，2018，8：203-210.
|
| ［33］ |
Frias JP，Deenadayalan S，Erichsen L，et al.Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes：a multicentre，randomised，double-blind，active-controlled，phase 2 trial ［J］.Lancet，2023，402（10403）：720-730.
|
| ［34］ |
Finan B，Yang B，Ottaway N，et al.A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents ［J］.Nat Med，2015，21（1）：27-36.
|
| ［35］ |
Jall S，Sachs S，Clemmensen C，et al.Monomeric GLP-1/GIP/glucagon triagonism corrects obesity，hepatosteatosis，and dyslipidemia in female mice ［J］.Mol Metab，2017，6（5）：440-446.
|
| ［36］ |
Bossart M，Wagner M，Elvert R，et al.Effects on weight loss and glycemic control with SAR441255，a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist ［J］.Cell Metab，2022，34（1）：59-74.
|
| ［37］ |
Rosenstock J，Frias J，Jastreboff AM，et al.Retatrutide，a GIP，GLP-1 and glucagon receptor agonist，for people with type 2 diabetes：a randomised，double-blind，placebo and active-controlled，parallelgroup，phase 2 trial conducted in the USA ［J］.Lancet，2023，402（10401）：529-544.
|
| ［38］ |
Jastreboff AM，Kaplan LM，Frias JP，et al.Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial ［J］.N Engl J Med，2023，389（6）：514-526.
|
| ［39］ |
Coskun T，Urva S，Roell W C，et al.LY3437943，a novel triple glucagon，GIP，and GLP-1 receptor agonist for glycemic control and weight loss：from discovery to clinical proof of concept ［J］.Cell Metab，2022，34（9）：1234-1247.
|
| ［40］ |
Lutz TA.Control of food intake and energy expenditure by amylintherapeutic implications ［J］.Int J Obes （Lond），2009，33（Suppl 1）：S24-S27.
|
| ［41］ |
Hollander P，Maggs DG，Ruggles JA，et al.Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients ［J］.Obes Res，2004，12（4）：661-668.
|
| ［42］ |
Gydesen S，Andreassen KV，Hjuler ST，et al.Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog ［J］.Am J Physiol Endocrinol Metab，2017，313（5）：E598-E607.
|
| ［43］ |
Srivastava G，Apovian C.Future pharmacotherapy for obesity：new anti-obesity drugs on the horizon ［J］.Curr Obes Rep，2018，7（2）：147-161.
|
| ［44］ |
Lau D，Erichsen L，Francisco AM，et al.Once-weekly cagrilintide for weight management in people with overweight and obesity：a multicentre，randomised，double-blind，placebo-controlled and activecontrolled，dose-finding phase 2 trial ［J］.Lancet，2021，398（10317）：2160-2172.
|
| ［45］ |
Stadlbauer U，Woods SC，Langhans W，et al.PYY3-36：Beyond food intake ［J］.Front Neuroendocrinol，2015，38：1-11.
|
| ［46］ |
Batterham RL，Cowley MA，Small CJ，et al.Gut hormone PYY （3-36） physiologically inhibits food intake ［J］.Nature，2002，418（6898）：650-654.
|
| ［47］ |
Adams TD，Davidson LE，Litwin SE，et al.Weight and metabolic outcomes 12 years after gastric bypass ［J］.N Engl J Med，2017，377（12）：1143-1155.
|
| ［48］ |
Mok J，Adeleke MO，Brown A，et al.Safety and efficacy of liraglutide，3.0 mg，once daily vs placebo in patients with poor weight loss following metabolic surgery：the BARI-OPTIMISE randomized clinical trial ［J］.JAMA Surg，2023，158（10）：1003-1011.
|
| ［49］ |
Thakur U，Bhansali A，Gupta R，et al.Liraglutide augments weight loss after laparoscopic sleeve gastrectomy：a randomised，double-Blind，placebo-control study ［J］.Obes Surg，2021，31（1）：84-92.
|
| ［50］ |
Hany M，Torensma B，Ibrahim M，et al.Boosting weight loss after conversional Roux-en-Y gastric bypass with liraglutide and placebo use.A double-blind-randomized controlled trial ［J］.Int J Surg，2024，110（3）：1546-1555.
|
| ［51］ |
Badurdeen D，Hoff AC，Barrichello S，et al.Efficacy of liraglutide to prevent weight regain qfter retrieval of an adjustable intra-gastric balloon-a case-matched study ［J］.Obes Surg，2021，31（3）：1204-1213.
|
| ［52］ |
Yilmaz A，Hanlioglu S，Demiral G，et al.The efficacy of liraglutide combined with intragastric balloon on weight loss ［J］.Rev Assoc Med Bras （1992），2023，69（12）：e20230571.
|
| ［53］ |
Ludvik B，Giorgino F，Jodar E，et al.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes （SURPASS-3）：a randomised，open-label，parallel-group，phase 3 trial ［J］.Lancet，2021，398（10300）：583-598.
|